Standout Papers
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management (2010)
- A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis (2006)
- Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study (2009)
- Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry (2009)
- Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011)
Immediate Impact
5 from Science/Nature 100 standout
Citing Papers
Ulcerative colitis
2023 Standout
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
2021 Standout
Works of Marc Lémann being referenced
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
2011
Risk Factors Associated With Small Bowel Adenocarcinoma in Crohn's Disease: A CaseControl Study
2008
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Marc Lémann | 8323 | 7033 | 4305 | 176 | 12.8k | |
| R Modigliani | 7752 | 5865 | 4085 | 161 | 13.0k | |
| Gary R. Lichtenstein | 11759 | 9533 | 3889 | 131 | 14.0k | |
| Jack Satsangi | 9208 | 6151 | 3956 | 207 | 12.9k | |
| Édouard Louis | 8614 | 6324 | 3811 | 372 | 13.1k | |
| Jean–Frédéric Colombel | 8733 | 6489 | 3644 | 205 | 13.9k | |
| Jacques Cosnes | 8377 | 7236 | 4455 | 232 | 13.0k | |
| Axel Dignaß | 9666 | 6862 | 4949 | 272 | 16.7k | |
| Sandro Ardizzone | 6746 | 5138 | 3507 | 229 | 10.4k | |
| Daniel H. Present | 13363 | 10011 | 5346 | 134 | 17.6k | |
| Antoine Cortot | 11509 | 8183 | 5930 | 274 | 19.0k |
All Works
Loading papers...